FDA Approves Unknown Drug — CIPLA

# FDA Approves CIPLA Generic Drug Application Cipla Limited has received FDA approval for its abbreviated new drug application (ANDA 211595), expanding the company's generic pharmaceutical portfolio and positioning it to capture additional market share in the competitive U.S. generics sector. The approval strengthens Cipla's ability to meet domestic demand while leveraging cost advantages typical of generic drug offerings.